Direct Acting Agents in Hepatitis C Patients

Fehmi Tabak2,700 enrolled

Overview

This study is a retrospective study conducted at 36 sites. Planned target patient number is 1000.

Approximately 36 centers will be included in Turkey. Centers will be selected from clinics of infection and clinical microbiology. The inclusion of 1000 patients was targeted. All data will be retrospectively collected from the medical records of the patients. Patient visit is not necessary.

Study Type

OBSERVATIONAL

Enrollment

2,700

Conditions

Hepatitis C Hepatitis C Relapse Hepatitis C Recurrent

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who used direct acting agents for Hepatitis C Exclusion Criteria: * Patients younger then 18 years

Locations (1)

Cerrahpasa Medical Faculty

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

Disease management with direct acting agents

To assess disease management of chronic hepatitis C patients using direct acting agents (DAA) at national level, especially change in HCVRNA levels 12 weeks after the 24 weeks treatment (SVR12)

Time frame: Beginning of treatment - 12 weeks after the treatment ended (36 weeks)

Secondary Outcomes

Incidence of Treatment-Emergent Adverse Events

Adverse event list according to CTCAE v.4.03

Time frame: Up to 48 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.